HOME >> BIOLOGY >> NEWS
Epimmune scientists report positive pre-clinical data on vaccine designed to combat HIV's ability to mutate

who do not progress to AIDS for long periods even without anti-retroviral drug therapy. Epimmunes approach to vaccine development is based on epitopes from non-mutating regions of multiple virus proteins that are specifically selected for their ability to stimulate two types of cellular immunity, cytotoxic T-cells (CTLs) and helper T-cells (HTLs). Together, CTLs and HTLs comprise the bodys natural defense against HIV in which CTLs are capable of directly destroying virus-infected cells but require HTLs, which produce immune-boosting chemicals, for proper functioning.

Epimmune has designed its vaccine to provide immunity against many HIV clades (HIV strains that are common to a certain geographical region), including those that are prevalent in the United States, Europe, Africa and India. The vaccine is also designed to provide broad population coverage regardless of ethnicity.

Epimmunes vaccine will be delivered as DNA in combination with PVP, a polymer gene delivery technology licensed from Valentis, Inc. The PVP polymer has been shown to increase the efficiency of vaccine uptake by immune cells and enhance potency in animal studies. Epimmune has also linked its HIV vaccine with its proprietary PADRE universal helper T-cell epitope. PADRE is an HTL booster which, when combined with CTL epitopes, enhances the magnitude and duration of the immune response. Finally, the vaccine construct has also been optimized to ensure that the epitopes are processed efficiently and correctly once inside the cell. The epitopes are placed in a specific order (like beads on a string) that allows cellular enzymes to recognize the appropriate places to liberate the epitopes from the chain, thus improving the efficiency and potency of the vaccine.


'"/>

Contact: Laura Hansen
lhansen@irpr.com
858-860-0266
Epimmune, Inc.
1-Apr-2001


Page: 1 2

Related biology news :

1. DNA lends scientists a hand, revealing new chemical reactions
2. Conference at UH opens doors for new scientists, engineers
3. Wisconsin scientists develop quick botox test
4. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
5. Alaska scientists find Arctic tundra yields surprising carbon loss
6. UAF scientists discover new marine habitat in Alaska
7. Information system to help scientists analyze mechanisms of social behavior
8. Zoonotic diseases - European scientists unite to fight diseases
9. Israeli scientists reveal the plan of a key cellular machine
10. Study by Israeli scientists provides insight on DNA code
11. Computer scientists at UH developing nurturing computers

Post Your Comments:
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) explores ... the impact of coffee on autoimmune disease and palliative ... recently has been associated with reduced risk of fibrosis, ... cups of java each month also correlate with lower ... the Mayo Clinic, Rochester, MN, linked coffee consumption with ...
(Date:5/17/2013)... Researchers at Rutgers, The State University of New Jersey, ... proprietary new formulation called Visikol TM that effectively ... be used in place of chloral hydrate, which is ... but which is tightly regulated by the Drug Enforcement ... , Clearing solutions, or clearing agents, are vital for ...
(Date:5/17/2013)... climate change may have little impact on many ... recent studies that predict their widespread extinction in ... appear in the journal Global Change Biology ... creature thought to be doomed: http://onlinelibrary.wiley.com/doi/10.1111/gcb.12253/abstract ... forest lizards, will be hard hit by climate ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3Climate change may have little impact on tropical lizards 2
(Date:5/20/2013)... May 21, 2013 Grace Century ... in “game-changing” life science and health related private equity ... to its International Project Team. Dergham's expertise in finance ... multi-cultural depth to Grace Century as it continues to ... , Ms. Dergham holds both an under graduate degree ...
(Date:5/20/2013)... Calif. , May 20, 2013  (PSHR) ... providing naturally based products across a broad range ... company has retained investor relations firm, BlueWater Advisory ... the return to trading process, and to direct ... trading initiation. Matthew Mills ...
(Date:5/20/2013)... , Md. and BALTIMORE , May ... (BHI), a regional private-public partnership focusing on commercializing ... funding in Central Maryland , ... M.B.A., as the first Entrepreneur-in-Residence (EIR) for BHI ... National Heart, Lung and Blood Institute (NHLBI). ...
(Date:5/20/2013)... Interventional cardiologist Tony Farah, MD, and his colleagues ... Institute have helped pioneer many breakthroughs in the ... the past three decades, from new disease-fighting medications to ... stent implantation. , Today, AGH officials announced that the ... the study of a novel, first-of-its kind investigational device ...
Breaking Biology Technology:Dalia Dergham Joins Grace Century FZ LLC International Project Team 2Pacific Shore Holdings Retains Investor Relations Firm 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4
Cached News: